CN111939443A

CN111939443A - Nasal cavity sustained-release drug delivery device

Info

Publication number: CN111939443A
Application number: CN202010861227.0A
Authority: CN
Inventors: 徐维林; 阮明波; 宋平; 宫雪; 杨吉
Original assignee: Changchun Institute of Applied Chemistry of CAS
Current assignee: Changchun Institute of Applied Chemistry of CAS
Priority date: 2020-08-25
Filing date: 2020-08-25
Publication date: 2020-11-17

Abstract

The invention relates to a nasal cavity sustained-release drug delivery device, and belongs to the technical field of nasal cavity drug delivery devices. The problem of among the prior art gaseous medicine and volatile medicine nasal cavity inconvenient of dosing is solved to can slowly last provide the medicine, alleviate patient's discomfort. The nasal cavity drug delivery device comprises a bracket and a sustained-release tablet; the bracket comprises two medicine carrying seats, wherein the two medicine carrying seats are of columnar structures with two open ends and can be respectively placed in the two nostrils; the bottom end opening of each medicine carrying seat is provided with a ventilating baffle; a snap ring is arranged on the inner wall of the medicine carrying seat between the air baffle and the opening at the top end of the medicine carrying seat; the slow release tablet is of a sheet structure with air holes and is arranged between the air permeable baffle and the snap ring. This nasal cavity sustained-release drug delivery device easy operation when dosing inhales the nasal cavity with the medicine molecule of tablet slowly-releasing through breathing to guarantee that the medicine can be sustainably carried out the nasal cavity and dosed slowly, avoid the discomfort that the big dose caused of dosing, it is more comfortable when the patient doses.

Description

Nasal cavity sustained-release drug delivery device

Technical Field

The invention belongs to the technical field of nasal cavity drug delivery devices, and particularly relates to a nasal cavity sustained-release drug delivery device.

Background

The nasal cavity is used as the initial part of the respiratory system, is divided into a left cavity and a right cavity by the nasal septum, is communicated with the outside by the front nostril and is connected with the lung by the throat, and is a very important organ of the human body. The total area of nasal mucosa in nasal cavity is about 150cm²The mucous membrane is rich in capillary vessels, the lung has a large surface area and large blood flow, the cell structure of the alveolus is thin, and the mucous membrane and the alveolus can well absorb the medicine, so that the nasal administration is an administration mode which is easy to absorb.

Nasal administration to the respiratory tract has many advantages in addition to rapid drug absorption, such as: the medicine has no gastrointestinal degradation effect and liver first-pass effect, directly enters systemic circulation after being absorbed, can achieve the purpose of systemic treatment, is quick to absorb, quick to take effect after administration, high in bioavailability, and good in nasal administration effect of some medicines which are difficult to absorb, can avoid local tissue allergy, degeneration or necrosis caused by long-term subcutaneous injection, is convenient to administer and easy to accept by patients, and can avoid the total dose of single administration due to the limited volume of the nasal cavity. In the prior art, aerosol or powder spray is generally used for nasal administration, no good administration device is available for administration of gas medicines or volatile liquid medicines, and discomfort is easily caused by too large single administration dose.

Disclosure of Invention

In view of the above, the invention provides a nasal cavity sustained-release drug delivery device, which solves the problem that the administration of gas drugs and volatile drugs through nasal cavities is inconvenient in the prior art, and can slowly and continuously provide the drugs and relieve the discomfort of patients.

The technical scheme adopted by the invention for solving the technical problems is as follows.

The nasal cavity sustained-release drug delivery device comprises a bracket and a sustained-release tablet;

the bracket comprises two medicine carrying seats, the two medicine carrying seats are of a columnar structure with two open ends, the outer contours of the two medicine carrying seats are respectively matched with two nostrils of a human body, and the two medicine carrying seats can be respectively placed in the two nostrils; the bottom end opening of each medicine carrying seat is provided with a ventilating baffle; a snap ring is arranged on the inner wall of the medicine carrying seat between the air baffle and the opening at the top end of the medicine carrying seat, and the outer edge of the snap ring is fixed along the inner wall of the medicine carrying seat;

the slow release tablet is of a sheet structure with air holes and is arranged between the air permeable baffle and the clamping ring; the sustained-release tablet is prepared by uniformly mixing the drug, the hydrogel, the cross-linking agent and the solvent, and then filling the mixture into a mould for shaping, wherein the mass ratio of the drug, the hydrogel, the cross-linking agent and the solvent is (1-10): (1-10) (:1-5): 1-50).

Further, the support also comprises a connecting rod for connecting the two medicine carrying seats.

Furthermore, the air-permeable baffle plate is composed of two strip-shaped plates arranged in a cross shape, and two ends of the two strip-shaped plates are fixed on the inner wall of the medicine carrying seat.

Furthermore, the thickness of the sustained-release tablet is 1-5 mm.

Furthermore, the air holes of the slow-release tablet are of a honeycomb structure.

Further, the medicine is volatile essential oil, beclomethasone or hydrocortisone.

Furthermore, the hydrogel is hyaluronic acid gel, chitosan, sodium alginate, polyacrylamide, polyvinyl alcohol or polyvinylpyrrolidone.

Further, the cross-linking agent is benzoyl peroxide, dicumyl peroxide or di-tert-butyl peroxide.

Further, the solvent is water, ethanol or glycerol.

Furthermore, the bracket is integrally formed and made of an elastic high polymer material; furthermore, the elastic polymer material is silica gel, hydrogenated styrene-butadiene copolymer (SEBS) or polyolefin elastomer (POE).

Compared with the prior art, the invention has the beneficial effects that:

the nasal cavity sustained-release drug delivery device provided by the invention dissolves the drug in the solvent, the solvent is slowly volatilized by utilizing the moisturizing effect of the hydrogel, and the drug molecules are slowly volatilized along with the solvent, so that the drug sustained-release effect is achieved.

The nasal cavity sustained-release drug delivery device is simple to operate during drug delivery, drug molecules sustained-released by the tablets are inhaled into the nasal cavity through breathing, the drug is ensured to be continuously and slowly delivered to the nasal cavity, discomfort caused by large-dose drug delivery is avoided, and a patient feels more comfortable during drug delivery.

Drawings

In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.

FIG. 1 is a schematic view of the structure of a sustained release tablet of the nasal sustained release delivery device of the present invention;

FIG. 2 is a top view of a stent of the nasal sustained release delivery device of the present invention;

FIG. 3 is a schematic structural diagram of a nasal sustained release drug delivery device of the present invention;

FIG. 4 is a perspective view of the nasal sustained release delivery device of the present invention;

in the figure, 1, a slow-release tablet, 11, air holes, 2, a bracket, 21, a clamping ring, 22, a medicine carrying seat, 23, an air-permeable baffle, 24 and a connecting rod.

Detailed Description

For a further understanding of the invention, preferred embodiments of the invention are described below in conjunction with the detailed description, but it is to be understood that the description is intended to further illustrate the features and advantages of the invention and not to limit the claims to the invention.

As shown in figures 1-4, the nasal sustained-release drug delivery device of the invention comprises a bracket 2 and a sustained-release tablet 1.

Wherein, support 2 includes two medicine carrying seat 22, and two medicine carrying seat 22 are both the both ends open-ended columnar structure, and the outline cooperates with two nostrils of human body respectively, can place respectively in two nostrils, accords with human engineering design. Be equipped with ventilative baffle 23 on the bottom opening of every medicine carrying seat 22, preferably, ventilative baffle 23 comprises two strip shaped plates that are the cross setting, and the both ends of two strip shaped plates all are fixed on the inner wall of medicine carrying seat 22. Be equipped with snap ring 21 on the inner wall of medicine carrying seat 22 between the top end opening of air baffle 23 and medicine carrying seat 22, snap ring 21 is the annular, and outline and the inner wall cooperation of medicine carrying seat 22, the outward flange is fixed along the inner wall of medicine carrying seat 22.

The sustained-release tablet 1 has a sheet-like structure, and preferably has a thickness of 1-5 mm. The sustained-release tablet 1 is provided with one or more air holes 11, preferably a plurality of air holes 11 which are uniformly distributed, and more preferably a plurality of air holes 11 which form a honeycomb structure. The sustained-release tablet 1 is prepared by uniformly mixing a drug, hydrogel, a cross-linking agent and a solvent, and then filling the mixture into a mold for shaping, wherein the mass ratio of the drug, the hydrogel, the cross-linking agent and the solvent is (1-10): (1-10) (:1-5): 1-50), preferably 1: (5-10):2: 25; the drug molecules can be volatile essential oil, beclomethasone or hydrocortisone; the hydrogel can be hyaluronic acid gel, chitosan, sodium alginate, polyacrylamide, polyvinyl alcohol or polyvinylpyrrolidone; the cross-linking agent can be benzoyl peroxide, dicumyl peroxide or di-tert-butyl peroxide; the solvent may be water, ethanol or glycerol.

The slow-release tablet 1 is placed between the air-permeable baffle plate 23 and the snap ring 21, the slow-release tablet 1 is matched with the bracket 2 for use, and the bracket 2 with a specific size fixes the slow-release tablet 1 with a corresponding size.

In the above technical solution, the bracket 2 further comprises a connecting rod 24 connecting the two drug-loaded seats 22, and the specific length and the setting position conform to the ergonomic design.

In the above technical solution, the support 2 is usually integrally formed, and is made of an elastic polymer material, such as silica gel, hydrogenated styrene-butadiene copolymer or polyolefin elastomer.

The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified.

In order to make those skilled in the art better understand the technical solution of the present invention, the present invention will be further described in detail with reference to the following embodiments.

In the following examples, various procedures and methods not described in detail are conventional methods well known in the art. Materials, reagents, devices, instruments, apparatuses and the like used in the following examples are commercially available unless otherwise specified.

Example 1

The structure of the sustained-release tablet 1 is as described in the specific embodiment, the sustained-release tablet is prepared by uniformly mixing a medicine, hydrogel, a cross-linking agent and a solvent, and then filling the mixture into a mold for shaping, wherein the mass ratio of the medicine, the hydrogel, the cross-linking agent and the solvent is 1:5:2: 25; the drug molecules are volatile essential oil, the hydrogel is sodium alginate, the cross-linking agent is benzoyl peroxide, and the solvent is water.

In the technical scheme, the sandalwood essential oil is slowly released along with the volatilization of water, so that the effects of relieving pressure and soothing nerves can be achieved.

Example 2

The structure of the sustained-release tablet 1 is as described in the specific embodiment, the sustained-release tablet is prepared by uniformly mixing a drug, hydrogel, a cross-linking agent and a solvent, and then filling the mixture into a mold for shaping, wherein the mass ratio of drug molecules, hydrogel, cross-linking agent and solvent is 1:10:2: 25; the drug molecule is beclomethasone, the hydrogel is hyaluronic acid gel, the cross-linking agent is benzoyl peroxide, and the solvent is water.

In the technical scheme, beclomethasone is slowly released along with the volatilization of water, so that the effect of treating allergic rhinitis can be achieved.

It should be understood that the above embodiments are only examples for clearly illustrating the present invention, and are not intended to limit the present invention. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the spirit or scope of the invention.

Claims

1. The nasal cavity sustained-release drug delivery device is characterized by comprising a bracket (2) and a sustained-release tablet (1);

the bracket (2) comprises two medicine carrying seats (22), the two medicine carrying seats (22) are of a columnar structure with two open ends, the outer contour of each medicine carrying seat is matched with two nostrils of a human body respectively, and the medicine carrying seats can be placed in the two nostrils respectively; an air-permeable baffle plate (23) is arranged on the bottom opening of each medicine carrying seat (22); a snap ring (21) is arranged on the inner wall of the medicine carrying seat (22) between the air baffle (23) and the opening at the top end of the medicine carrying seat (22), and the outer edge of the snap ring (21) is fixed along the inner wall of the medicine carrying seat (22);

the slow-release tablet (1) is of a sheet structure with air holes (11) and is placed between the air-permeable baffle plate (23) and the clamping ring (21); the sustained-release tablet (1) is formed by uniformly mixing a drug, hydrogel, a cross-linking agent and a solvent, and then filling the mixture into a mould for shaping, wherein the mass ratio of the drug, the hydrogel, the cross-linking agent and the solvent is (1-10): (1-10) (:1-5): 1-50).

2. A device for the slow-release administration to the nasal cavity according to claim 1, characterised in that said frame (2) further comprises a connecting rod (24) connecting the two drug-loaded seats (22).

3. The device for the slow-release administration of drugs through nasal cavities according to claim 1, characterized in that said air-permeable baffle (23) is composed of two strips arranged in a cross shape, both ends of the two strips are fixed on the inner wall of the drug-carrying seat (22).

4. The nasal sustained release delivery device according to claim 1, wherein the sustained release tablet (1) has a thickness of 1-5 mm.

5. The nasal sustained-release drug delivery device according to claim 1, wherein the air holes (11) of the sustained-release tablet (1) have a honeycomb structure.

6. The device as claimed in claim 1, wherein the drug is volatile essential oil, beclomethasone or hydrocortisone.

7. The nasal sustained release delivery device of claim 1, wherein the hydrogel is hyaluronic acid, chitosan, sodium alginate, polyacrylamide, polyvinyl alcohol, or polyvinylpyrrolidone.

8. The device for the sustained nasal delivery according to claim 1, wherein the cross-linking agent is benzoyl peroxide, dicumyl peroxide or di-t-butyl peroxide.

9. The nasal sustained release delivery device of claim 1, wherein the solvent is water, ethanol or glycerol.

10. The nasal cavity sustained-release drug delivery device according to claim 1, characterized in that the stent (2) is integrally molded and made of an elastic polymer material, and the elastic polymer material is silica gel, hydrogenated styrene-butadiene copolymer or polyolefin elastomer.